Skip to main content
Top
Published in: Tumor Biology 10/2016

01-10-2016 | Original Article

CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients

Authors: Brigitte Rack, Julia Jückstock, Elisabeth Trapp, Tobias Weissenbacher, Marianna Alunni-Fabbroni, Amelie Schramm, Peter Widschwendter, Krisztian Lato, Thomas Zwingers, Ralf Lorenz, Hans Tesch, Andreas Schneeweiss, Peter Fasching, Sven Mahner, Matthias W. Beckmann, Werner Lichtenegger, Wolfgang Janni, For the SUCCESS Study Group

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

Several trials showed that tumour markers are associated with an impaired prognosis for breast cancer. Whether earlier treatment can improve the course of the disease remains controversial. The SUCCESS Trial compares FEC (500/100/500)-docetaxel (100) vs. FEC (500/100/500)-docetaxel/gemcitabine (75/2000) as well as 2 vs. 5 years of zoledronate in high-risk primary breast cancer patients. In 2669 patients, CA27.29 was measured before and after chemotherapy with the ST AIA-PACK CA27.29 reagent for the AIA-600II automated enzyme immunoassay (Tosoh Bioscience, Belgium). Values above 31 U/ml were considered positive. Of the patients, 7.6 % (n = 202, mean 19, range 3–410) and 19.1 % (n = 511, mean 21, range 3–331) had elevated marker levels before and after chemotherapy, respectively. Of the patients, 4.9 and 78 % showed elevated and low CA27.29, respectively, at both time points. After treatment, 35 % of the pre-therapy positive patients were negative, and 15 % of the initially negative patients became positive. The correlation between both time points was significant (p < 0.0001). No correlations among nodal status, grading, hormonal status, HER2 status and CA27.29 levels were found. However, tumour size (p = 0.02), older age (p < 0.001) and post-menopausal status (p = 0.006) were significantly associated with higher CA27.29 levels. Before treatment, the prevalence of elevated CA27.29 was equally distributed between both treatment arms, whereas after chemotherapy, 13.7 % of the patients in the FEC-doc arm showed an increased level vs. 25.4 % of the patients in the FEC-doc/gemcitabine arm (p < 0.0001). However, we could not show a significant association between the G-CSF application (yes vs. no) and CA27.29 status before/after chemotherapy (p = 0.75). These results indicate a close relationship between CA27.29 levels and tumour mass. Increased values after the completion of chemotherapy might be attributed to treatment effects and should be considered with caution.
Literature
2.
go back to reference Allemani C, Sant M, Weir HK, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer. 2013;132:1170–81.CrossRefPubMed Allemani C, Sant M, Weir HK, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer. 2013;132:1170–81.CrossRefPubMed
3.
go back to reference Allemani C, Minicozzi P, Berrino F, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002. Int J Cancer. 2013;132:2404–12.CrossRefPubMed Allemani C, Minicozzi P, Berrino F, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002. Int J Cancer. 2013;132:2404–12.CrossRefPubMed
5.
go back to reference Gion M, Boracchi P, Dittadi R, et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer. 2002;38:1181–8.CrossRefPubMed Gion M, Boracchi P, Dittadi R, et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer. 2002;38:1181–8.CrossRefPubMed
6.
go back to reference Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat. 2002;76:95–102.CrossRefPubMed Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat. 2002;76:95–102.CrossRefPubMed
7.
go back to reference Brouckaert O, Laenen A, Wildiers H, et al. The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. Breast. 2013;22:254–62.CrossRefPubMed Brouckaert O, Laenen A, Wildiers H, et al. The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. Breast. 2013;22:254–62.CrossRefPubMed
8.
go back to reference Sandri MT, Salvatici M, Botteri E, et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Res Treat. 2012;132:317–26.CrossRefPubMed Sandri MT, Salvatici M, Botteri E, et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Res Treat. 2012;132:317–26.CrossRefPubMed
9.
go back to reference Keshaviah A, Dellapasqua S, Rotmensz N, et al. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven international breast cancer study group trials. Ann Oncol. 2007;18:701–8.CrossRefPubMed Keshaviah A, Dellapasqua S, Rotmensz N, et al. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven international breast cancer study group trials. Ann Oncol. 2007;18:701–8.CrossRefPubMed
10.
go back to reference Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer. 2002;38:1189–93.CrossRefPubMed Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer. 2002;38:1189–93.CrossRefPubMed
11.
go back to reference Nicolini A, Tartarelli G, Carpi A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006;6:269.CrossRefPubMedPubMedCentral Nicolini A, Tartarelli G, Carpi A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006;6:269.CrossRefPubMedPubMedCentral
13.
go back to reference Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.CrossRefPubMed Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.CrossRefPubMed
14.
go back to reference Singletary ES, Allred C, Ashley P, et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36.CrossRefPubMed Singletary ES, Allred C, Ashley P, et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–36.CrossRefPubMed
15.
go back to reference le Doussal V, Tubiana HM, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989;64:1914–21.CrossRefPubMed le Doussal V, Tubiana HM, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989;64:1914–21.CrossRefPubMed
16.
go back to reference Sinn BV, von Minckwitz G, Denkert C, et al. Evaluation of mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann.Oncologia. 2013;24:2316–24.CrossRef Sinn BV, von Minckwitz G, Denkert C, et al. Evaluation of mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann.Oncologia. 2013;24:2316–24.CrossRef
18.
go back to reference Park BW, JW O, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19:675–81.CrossRefPubMed Park BW, JW O, Kim JH, et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19:675–81.CrossRefPubMed
19.
go back to reference Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer. 1990;65:193–9.CrossRefPubMed Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer. 1990;65:193–9.CrossRefPubMed
20.
go back to reference Yasasever V, Dincer M, Camlica H, Karaloglu D, Dalay N. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on “spiking” phenomena. Clin Biochem. 1997;30:53–6.CrossRefPubMed Yasasever V, Dincer M, Camlica H, Karaloglu D, Dalay N. Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on “spiking” phenomena. Clin Biochem. 1997;30:53–6.CrossRefPubMed
21.
go back to reference Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, et al. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte—colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy. Cancer. 2004;101:1767–75.CrossRefPubMed Pentheroudakis G, Malamou-Mitsi V, Briasoulis E, et al. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte—colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy. Cancer. 2004;101:1767–75.CrossRefPubMed
22.
go back to reference Ghosh SK, Pantazopoulos P, Medarova Z, Moore A. Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin Breast Cancer. 2013;13:109–18.CrossRefPubMed Ghosh SK, Pantazopoulos P, Medarova Z, Moore A. Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin Breast Cancer. 2013;13:109–18.CrossRefPubMed
23.
go back to reference Demichelis SO, Alberdi CG, Servi WJ, Isla-Larrain MT, Segal-Eiras A, Croce MV. Comparative immunohistochemical study of MUC1 and carbohydrate antigens in breast benign disease and normal mammary gland. Appl Immunohistochem Mol Morphol. 2010;18:41–50.CrossRefPubMed Demichelis SO, Alberdi CG, Servi WJ, Isla-Larrain MT, Segal-Eiras A, Croce MV. Comparative immunohistochemical study of MUC1 and carbohydrate antigens in breast benign disease and normal mammary gland. Appl Immunohistochem Mol Morphol. 2010;18:41–50.CrossRefPubMed
24.
go back to reference Bon GG, van Kamp GJ, Verstraeten RA, Mensdorff-Pouilly S, Hilgers J, Kenemans P. Quantification of MUC1 in breast cancer patients. A method comparison study. Eur J Obstet Gynecol Reprod Biol. 1999;83:67–75.CrossRefPubMed Bon GG, van Kamp GJ, Verstraeten RA, Mensdorff-Pouilly S, Hilgers J, Kenemans P. Quantification of MUC1 in breast cancer patients. A method comparison study. Eur J Obstet Gynecol Reprod Biol. 1999;83:67–75.CrossRefPubMed
25.
go back to reference Duffy MJ, Duggan C, Keane R, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50:559–63.CrossRefPubMed Duffy MJ, Duggan C, Keane R, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50:559–63.CrossRefPubMed
26.
go back to reference Lynch DM, Rogers PE, Love JC, et al. Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA. Tumour Biol. 1998;19:421–38.CrossRefPubMed Lynch DM, Rogers PE, Love JC, et al. Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA. Tumour Biol. 1998;19:421–38.CrossRefPubMed
27.
go back to reference Gion M, Mione R, Leon AE, et al. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer. 2001;37:355–63.CrossRefPubMed Gion M, Mione R, Leon AE, et al. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer. 2001;37:355–63.CrossRefPubMed
28.
go back to reference Grassetto G, Fornasiero A, Otello D, et al. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. Eur J Radiol. 2011;80:828–33.CrossRefPubMed Grassetto G, Fornasiero A, Otello D, et al. 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. Eur J Radiol. 2011;80:828–33.CrossRefPubMed
Metadata
Title
CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients
Authors
Brigitte Rack
Julia Jückstock
Elisabeth Trapp
Tobias Weissenbacher
Marianna Alunni-Fabbroni
Amelie Schramm
Peter Widschwendter
Krisztian Lato
Thomas Zwingers
Ralf Lorenz
Hans Tesch
Andreas Schneeweiss
Peter Fasching
Sven Mahner
Matthias W. Beckmann
Werner Lichtenegger
Wolfgang Janni
For the SUCCESS Study Group
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5171-2

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine